|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions显示文摘During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2(HER-2) positive breast cancer. Trastuzumab, pertuzumab, adotrastuzumab emtansine and lapatinib are currently food and drug administration(FDA)-approved for the treatment of breast cancer patients with HER-2 overexpressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated informationrelated to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available. | Gonzalo Recondo Jr Enrique Dìaz Canton Màximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Clinical Oncology2014，5，3： | 7 |
| 2 | Advances and new perspectives in the treatment of metastatic colon cancer显示文摘During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new'standards of care'are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease. | Gonzalo Recondo Jr Enrique Díaz-Cantón Máximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Gastrointestinal Oncology2014，6，7： | 2 |
| 3 | Phytoplankton structure and dynamics in Lake Sanabria and Valparaiso reservoir (NW Spain)显示文摘 | Negro A I Hoyos C D Vega J | 2000 | Hydrobiologia2000，424，： | 1 |
| 4 | Depth of water uptake in woody plants relates to groundwa-ter 1eve|l and vegetation structure along a topographic gra- dient in a neotropical savanna 显示文摘 | Rossatto D R Silva L C R Villalobos - Vega R | 2012 | Environmental and Ex- perimental Botany2012，77，： | 1 |
| 5 | The influence of the type of resuscitation fluid on gut injury and distant organ injury in a rat model of trauma/hemorrhagic shock显示文摘 | Vega D Badami CD Caputo FJ | | 0，，02： | 1 |
| 6 | Characterization of urinary tract symptoms and quality of life in patients with double pig tailed ureteral stents显示文摘 | Vega Vega A Garcia Alonso D Garcia Alonso C J | 2007 | Actas Urol Esp2007，31，7： | 1 |
| 7 | Emergence of imipenem resistance in clinical Escherichia coli during therapy显示文摘 | Oteo J Delgado·lribarren A Vega D | 2008 | Int J Antimicrob Agents2008，32，6： | 1 |
| 8 | A multi - criteria GIS based procedure to solve a network compet- itive location problem 显示文摘 | Suarez - Vega R Santos - Penate D R Dorta - Gonzalez P | 2011 | Applied Geography2011，，1： | 1 |
| 9 | Emergence of imipenem resistance in clinical Escherichia coli during thera- py显示文摘 | Oteo J Delgado-Iribarren A Vega D | 2008 | Int Jantimicrob Agents2008，32，6： | 1 |
| 10 | A new device for alveolar bone transportation 显示文摘 | Vega O Perez D Ptiramo V | 2011 | Craniomaxillofac Trauma Reconstr2011，4，2： | 1 |
| 11 | A High Index of Suspicion: The Key to an Early Diagnosis of Wilson’s Disease in Childhood显示文摘 | Icíar Sánchez-Albisua Teresa Garde Loreto Hierro Carmen Camarena Esteban Frauca Angela de la Vega María Carmen Díaz Javier Larrauri Paloma Jara | 1999 | Journal of Pediatric Gastroenterology & Nutrition1999，，2： | 1 |
| 12 | Antigenic characterization of bovine viral diarrhoea virus isolates from spain with a panel of monoclonal antihodies显示文摘 | Vega S Rosell R Paton D J | 2000 | J Vet Med2000，47，： | 1 |
| 13 | The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution显示文摘 | Calvo D Dopazo J Vega MA | 1995 | Genomics1995，25，1： | 1 |
| 14 | Determination of deoxynivalenol in wheat by validated GCECD method~omparison with HPTLCACL13显示文摘 | Vega M Castillo D | 2006 | Electronic Journal of Food and Plants Chemistry2006，1，1： | 1 |
| 15 | Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl- xL Down-Regulation, and Chemosensitization of Nora Hodgkin' s Lymphoma B Cells by Rituximab 显示文摘 | Jazirehi AR Vega MI Chatterjee D | 2004 | Cancer Res2004，64，19： | 1 |
| 16 | Ochratoxin A occurrence in wines produced in Chile显示文摘 | Vega M Rios G von Baer D | 2012 | Food Control2012，28，： | 1 |
| 17 | The major genetic determinants of HIV-1control affect HLA class I peptide presentation显示文摘 | International HIV Controllers Study Pereyra F Jia X McLaren P J Telenti A de Bakker P I Walker B D Ripke S Brumme C J Pulit S L Carrington M Kadie C M Carlson J M Heckerman D Graham R R Plenge R M Deeks S G Gianniny L Crawford G Sullivan J Gonzalez E Davies L Camargo A Moore JM Beattie N Gupta S Crenshaw A Burtt N P Guiducci C Gupta N Gao X Qi Y Yuki Y Piechocka-Trocha A Cutrell E Rosenberg R Moss K L Lemay P O'Leary J Schaefer T Verma P Toth I Block B Baker B Rothchild A Lian J Proudfoot J Alvino D M Vine S Addo M M Allen T M Altfeld M Henn M R Le Gall S Streeck H Haas D W Kuritzkes D R Robbins G K Shafer R W Gulick R M Shikuma C M Haubrich R Riddler S Sax P E Daar E S Ribaudo H J Agan B Agarwal S Ahern R L Allen B L Altidor S Altschuler E L Ambardar S Anastos K Anderson B Anderson V Andrady U Antoniskis D Bangsberg D Barbaro D Barrie W Bartczak J Barton S Basden P Basgoz N Bazner S Bellos N C Benson A M Berger J Bernard N F Bernard A M Birch C Bodner S J Bolan R K Boudreaux E T Bradley M Braun J F Brndjar J E Brown S J Brown K Brown S T Burack J Bush LM Cafaro V Campbell O Campbell J Carlson R H Carmichael J K Casey K K Cavacuiti C Celestin G Chambers S T Chez N Chirch L M Cimoch P J Cohen D Cohn LE Conway B Cooper D A Cornelson B Cox D T Cristofano M V Cuchural G Jr Czartoski J L Dahman J M Daly J S Davis B T Davis K Davod S M DeJesus E Dietz C A Dunham E Dunn M E Ellerin T B Eron J J Fangman J J Farel C E Ferlazzo H Fidler S Fleenor-Ford A Frankel R Freedberg K A French N K Fuchs JD Fuller J D Gaberman J Gallant J E Gandhi R T Garcia E Garmon D Gathe J C Jr Gaultier C R Gebre W Gilman F D Gilson I Goepfert P A Gottlieb M S Goulston C Groger R K Gurley T D Haber S Hardwicke R Hardy W D Harrigan P R Hawkins T N Heath S Hecht F M Henry W K Hladek M Hoffman R P Horton J M Hsu R K Huhn G D Hunt P Hupert M J Illeman M L Jaeger H Jellinger R M John M Johnson J A Johnson K L Johnson H Johnson K Joly J Jordan W C Kauffman C A Khanlou H Killian R K Kim A Y Kim D D Kinder C A Kirchner J T Kogelman L Kojic E M Korthuis P T Kurisu W Kwon D S LaMar M Lampiris H Lanzafame M Lederman M M Lee D M Lee J M Lee M J Lee E T Lemoine J Levy J A Llibre J M Liguori M A Little S J Liu A Y Lopez A J Loutfy M R Loy D Mohammed D Y Man A Mansour M K Marconi V C Markowitz M Marques R Martin J N Martin H L Jr Mayer K H McElrath M J McGhee T A McGovern B H McGowan K McIntyre D Mcleod GX Menezes P Mesa G Metroka CE Meyer-Olson D Miller A O Montgomery K Mounzer K C Nagami E H Nagin I Nahass R G Nelson M O Nielsen C Norene D L O'Connor D H Ojikutu B O Okulicz J Oladehin O O Oldfield E C Olender S A Ostrowski M Owen WF Jr Pae E Parsonnet J Pavlatos A M Perlmutter A M Pierce M N Pincus J M Pisani L Price L J Proia L Prokesch R C Pujet H C Ramgopal M Rathod A Rausch M Ravishankar J Rhame F S Richards C S Richman D D Rodes B Rodriguez M Rose R C 3rd Rosenberg E S Rosenthal D Ross P E Rubin D S Rumbaugh E Saenz L Salvaggio M R Sanchez WC Sanjana V M Santiago S Schmidt W Schuitemaker H Sestak P M Shalit P Shay W Shirvani V N Silebi V I Sizemore J M Jr Skolnik P R Sokol-Anderson M Sosman J M Stabile P Stapleton J T Starrett S Stein F Stellbrink H J Sterman FL Stone V E Stone D R Tambussi G Taplitz R A Tedaldi E M Telenti A Theisen W Torres R Tosiello L Tremblay C Tribble M A Trinh P D Tsao A Ueda P Vaccaro A Valadas E Vanig T J Vecino I Vega V M Veikley W Wade B H Walworth C Wanidworanun C Ward D J Warner D A Weber R D Webster D Weis S Wheeler D A White D J Wilkins E Winston A Wlodaver C G van't Wout A Wright D P Yang O O Yurdin D L Zabukovic B W Zachary K C Zeeman B Zhao M | 2010 | Science2010，330，6010： | 1 |
| 18 | Chemo- sensitization to cisplatin by inhibitors of the Fanconi ane- mia/BRCA pathway 显示文摘 | Chirnomas D Taniguchi T de la Vega M | 2006 | Mol Cancer Ther2006，5，4： | 1 |
| 19 | Diagnostic value of N-terminal pro-B-type natriuretie peptide (NT proB- NP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis 显示文摘 | Sascha D Philipp K Vega S | 2008 | Nephrol Dial Transplant2008，23，4： | 1 |
| 20 | Barriers to pharmaceutical care in Argentina 显示文摘 | UEMA S A VEGA E M ARMANDO P D | 2007 | Pharm World Sci2007，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员